1. 321 Maintenance olaparib for BRCA-mutated ovarian cancer (OC) patients in 1st line and platinum-sensitive relapsed (PSR) settings: maximizing treatment opportunities. (18th September 2019) Authors: Poveda, A; Sackeyfio, A; Friedlander, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study. (13th November 2020) Authors: Sivakumaran, T; Krasovitsky, M; Freimund, A; Chen Lee, K; Webber, K; So, J; Norris, C; Friedlander, M; Mileshkin, L; Au-Yeung, G Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study. (13th November 2020) Authors: Sivakumaran, T; Krasovitsky, M; Lee, YC; Norris, C; Friedlander, M Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. (17th December 2018) Authors: Deva, S; Lee, J-S; Lin, C-C; Yen, C-J; Millward, M; Chao, Y; Keam, B; Jameson, M; Hou, M-M; Kang, Y-K; Markman, B; Lu, C-H; Rau, K-M; Lee, K-H; Horvath, L; Friedlander, M; Hill, A; Wu, J; Hou, J; Desai, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 950POlaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. (23rd October 2018) Authors: Oza, A M; Cibula, D; Oaknin, A; Poole, C; Mathijssen, R H J; Sonke, G S; Colombo, N; Špaček, J; Vuylsteke, P; Hirte, H; Pfisterer, J; Plante, M; Hanker, L C; Fielding, A; Haddad, V; Chmielecki, J; Friedlander, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A double-blind comparison of clinical effects of Ropivacaine 0.5%, 0.75%, 1.0% and Bupivacaine 0.5%, injected epidurally, in patients undergoing hysterectomy. (March 1994) Authors: Finucane, BT; Sandler, AN; McKenna, J; Milner, A; Friedlander, M; Reid, D; Muzyka, D; Chan, V; O'Callaghan-Enright, S Journal: Regional anesthesia Issue: Volume 19(1994)Supplement 2 Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Comparison of image analysis and flow cytometric determination of cellular DNA content. Issue 2 (February 1991) Authors: Cope, C; Rowe, D; Delbridge, L; Philips, J; Friedlander, M Journal: Journal of clinical pathology Issue: Volume 44:Issue 2(1991) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LBA3Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (25th November 2018) Authors: Friedlander, M; Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A M; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E S; Bloomfield, R; Disilvestro, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial. (1st November 2019) Authors: Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Friedlander, M; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, GS; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Mathews, C; Liu, J; Lowe, ES; Bloomfield, R Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Postoperative radiotherapy in breast cancer. Issue 6282 (27th June 1981) Authors: Friedlander, M; Tattersall, M H Journal: BMJ Issue: Volume 282:Issue 6282(1981) Page Start: 2133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗